dec@seroconversion@sufficiently@nonreactive@years@ann intern med@children@modlin-j-f@placebo@antibody@im@ae@j-infect-dis@s626-31@asthma@humoral@j pediatr@eickhoff tc@dose@adolescence@protective@jama@male@jersey/76-a/victoria/75@suppl@reactivity@antigenic@doses@bi@differences@am j dis child@lung-diseases@two@virus@booster@pabico rc@in: strauss mb@categories@cystic-fibrosis@reaction@initial@split-product@aged@phillips cf@in: barnett hl@harding-l@trials@chronic-disease@associated@whole-virus@weil wb@adequate@seven@support-u-s-govt-p-h-s@marine wm@high@grant hb@unacceptably@titers@orthomyxovirus-type-a-human@j infect dis suppl@j virol@am acad pediatrics@female@administered@chronic@a/new@given@diabetes-mellitus-insulin-dependent@significant@a/victoria@clinical@reactive@immunization@bivalent@smith-d-h@relatively@heart-defects-congenital@child@influenza@vaccines@schriener ge@preparations@nicholas rv@jersey@induced@human@anon@j infect dis@six@disease@rates@high-risk@statistically@antibodies-viral@kilbourne ed@endocrine-diseases@vaccine@lerman sj@higgons ra@pd@various@response@healthy@pediatrics@reimer cb@risk@influenza-vaccine@